🔥🐔 BizChicken 🐔🔥

Companies Similar to Esperion Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Akero Therapeutics, Inc.

Akero Therapeutics, Inc. logo
Market Cap: High
Employees: Lowest

efruxifermin (EFX)

Akero Therapeutics, Inc., a cardio-metabolic NASH company, develops medicines for restoring metabolic balance and improving health. Efruxifermin (EFX) is its lead product, undergoing a Phase 2a clinical trial to treat NASH.

Tags: Biotechnology, Clinical Trials, Metabolic Health, NASH, Pharmaceuticals

Symbol: AKRO

Recent Price: $27.96

Industry: Biotechnology

CEO: Dr. Andrew Cheng M.D., Ph.D.

Sector: Healthcare

Employees: 61

Address: 601 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 487 6488

Last updated: 2024-12-31

DURECT Corporation

DURECT Corporation logo
Market Cap: Lowest
Employees: Lowest

ALZET

DURECT Corporation is a biopharmaceutical company that develops medicines based on its epigenetic regulator and pharmaceutical programs. It offers products like ALZET osmotic pumps for laboratory animal research, larsucosterol for treating liver diseases, and POSIMIR for post-surgical pain relief.

Tags: ALZET, POSIMIR, biopharmaceutical, epigenetic, larsucosterol, research

Symbol: DRRX

Recent Price: $0.85

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. James E. Brown D.V.M.

Sector: Healthcare

Employees: 48

Address: 10260 Bubb Road, Cupertino, CA 95014-4166

Phone: 408 777 1417

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

Sotagliflozin, LX9211

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products, with drugs like Sotagliflozin and LX9211 under development for heart failure, type 1 diabetes, and neuropathic pain.

Tags: biopharmaceutical, drug development, heart failure, neuropathic pain, type 1 diabetes

Symbol: LXRX

Recent Price: $0.72

Industry: Biotechnology

CEO: Dr. Michael Exton Ph.D.

Sector: Healthcare

Employees: 285

Address: 2445 Technology Forest Boulevard, The Woodlands, TX 77381

Phone: 281 863 3000

Leadership

  • Brian Corrigan, Senior Vice President, Regulatory and Quality Assurance
  • Brian Crum, Senior Vice President and General Counsel
  • Lisa DeFrancesco, Vice President, Investor Relations and Corporate Communications
  • Mike Exton, Ph.D., Chief Executive Officer and Director
  • Tom Garner, Senior Vice President and Chief Commercial Officer
  • Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer
  • Alan Main, PhD, Executive Vice President, Innovation and Chemical Sciences
  • Wendy McDermott, Senior Vice President, Human Resources
  • Kristen Alexander, Vice President, Finance and Accounting
  • Phillip Banks, MS, FRS, Vice President, Biostatistics and Data Management
  • Kyle Burt, Vice President, Information Operations
  • Amy Carroll, Ph.D., Vice President, Medical Affairs
  • Melinda Francini, Vice President, Value and Access
  • Desiree Gendron, Vice President, Sales and Training
  • Suma Gopinathan, Ph.D., Vice President, Clinical Development
  • Rachel Martens, Vice President, Partnerships and Corporate Strategy
  • Nicole Moore, Vice President, Legal
  • Tracy Newbold, Vice President, Clinical Operations
  • Godfried Owusu-Ababio, Vice President, Technical Operations
  • Rob Scala, Vice President, Business Planning and Commercial Operations
  • Carrie Siragusa, Vice President, Marketing
  • Dixon Terry, Vice President, Compliance
  • Raymond Debbane, Chairman
  • Philippe J. Amouyal,
  • Samuel L. Barker, PhD,
  • Robert J. Lefkowitz, MD,
  • Christopher J. Sobecki,
  • Diane E. Sullivan,
  • Judith L. Swain, MD,

Last updated: 2024-12-31

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ZYESAMI, NRX-100, NRX-101

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

Tags: CNS disorders, COVID-19 treatment, bipolar depression, clinical-stage pharmaceutical, pulmonary diseases, suicidal behavior

Symbol: NRXP

Recent Price: $1.53

Industry: Biotechnology

CEO: Dr. Jonathan C. Javitt M.D., M.P.H.

Sector: Healthcare

Employees: 2

Address: 1201 Orange Street, Wilmington, DE 19801

Phone: 484 254 6134

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Zunsemetinib

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases. It operates through Therapeutics and Contract Research segments, addressing unmet needs with innovative therapies, including treatments for rheumatoid and psoriatic arthritis, atopic dermatitis, autoimmune diseases, inflammatory bowel disease, and certain cancers.

Tags: atopic dermatitis, autoimmune diseases, biopharmaceutical, cancer, contract research, drug development, immune-inflammatory diseases, psoriatic arthritis, rheumatoid arthritis, therapeutics

Symbol: ACRS

Recent Price: $2.48

Industry: Medical - Diagnostics & Research

CEO: Dr. Neal S. Walker D.O., M.D.

Sector: Healthcare

Employees: 86

Address: 640 Lee Road, Wayne, PA 19087

Phone: 484 324 7933

Last updated: 2024-12-31

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

Sympazan, Suboxone, Zuplenz, Azstarys, Libervant, Exservan

Aquestive Therapeutics, Inc. is a pharmaceutical company committed to identifying, developing, and commercializing innovative products to address unmet medical needs, both in the U.S. and globally. It specializes in oral soluble film formulations for various treatments, including neurological conditions and opioid dependence.

Tags: ADHD, ALS, biotechnology, neurology, opioid dependence, oral soluble film, pharmaceutical

Symbol: AQST

Recent Price: $3.52

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Daniel Barber

Sector: Healthcare

Employees: 135

Address: 30 Technology Drive, Warren, NJ 07059

Phone: 908 941 1900

Last updated: 2024-12-31

Ardelyx, Inc.

Ardelyx, Inc. logo
Market Cap: High
Employees: Low

tenapanor

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.

Tags: CKD, biopharmaceutical, cardiorenal, gastrointestinal, hyperkalemia, hyperphosphatemia, metabolic acidosis, tenapanor

Symbol: ARDX

Recent Price: $5.25

Industry: Biotechnology

CEO: Mr. Michael G. Raab

Sector: Healthcare

Employees: 267

Address: 400 Fifth Avenue, Waltham, MA 02451

Phone: 510 745 1700

Leadership

  • Justin Renz, Chief Financial & Operations Officer
  • Eric Foster, Chief Commercial Officer
  • Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
  • Laura Williams, MD MPH, Chief Medical Officer
  • Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
  • David Rosenbaum, PhD, Chief Development Officer
  • Mike Kelliher, Executive Vice President, Corporate Development and Strategy
  • Charon Spencer, Chief Human Resources Officer
  • David Mott, Chairman
  • Robert Bazemore, Director
  • William A. Bertrand, Jr., JD, Director
  • Muna Bhanji, R.Ph, Director
  • Onaiza Cadoret-Manier, Director
  • Mike Raab, Director
  • Richard Rodgers, Director

Last updated: 2024-12-31

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELX-02

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.

Tags: ELX-02, biopharmaceutical, clinical trials, cystic fibrosis, nephropathic cystinosis, rare diseases, ribosome modulation

Symbol: ELOX

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Sumit Aggarwal M.B.A.

Sector: Healthcare

Employees: 18

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 781 577 5300

Last updated: 2024-12-31

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

NEXLETOL and NEXLIZET

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing medicines for treating elevated low density lipoprotein cholesterol. Its main products are NEXLETOL and NEXLIZET, aimed at treating conditions like atherosclerotic cardiovascular disease.

Tags: NEXLETOL, NEXLIZET, cardiovascular, cholesterol, medicine, pharmaceutical

Symbol: ESPR

Recent Price: $2.28

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Sheldon L. Koenig

Sector: Healthcare

Employees: 240

Address: 3891 Ranchero Drive, Ann Arbor, MI 48108

Phone: 734 887 3903

Leadership

  • Sheldon Koenig, Chief Executive Officer
  • Glenn Brame, Chief Technical Operations Officer
  • Ben Halladay, Chief Financial Officer, MBA
  • Benjamin O. Looker, General Counsel
  • Betty Jean (BJ) Swartz, Chief Business Officer
  • Eric Warren, R.Ph., Chief Commercial Officer
  • J. Martin Carroll, Chairman of the Board
  • Seth H.Z. Fischer, Member of the Compliance Committee Chair of the Compensation Committee
  • Alan Fuhrman, Chief Financial Officer
  • Antonio Gotto, Jr., MD, DPhil, Member of the Nominating and Governance Committee
  • Stephen Rocamboli, Chief Executive Officer of Innovatrx, Inc.
  • Jay Shepard, Venture Partner with Catalys Pacific
  • Nicole Vitullo, Lead Independent Director
  • Tracy Woody, Member of the Nominating and Governance Committee Chair of the Compliance Committee

Last updated: 2024-11-08

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

Heron Therapeutics, Inc.

Heron Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

SUSTOL, CINVANTI, ZYNRELEF

Heron Therapeutics, Inc. is a biotechnology company focused on developing treatments to address unmet patient needs, utilizing its proprietary Biochronomer drug delivery technology.

Tags: biotechnology, cancer treatment, chemotherapy, drug delivery, nausea prevention

Symbol: HRTX

Recent Price: $1.51

Industry: Biotechnology

CEO: Mr. Craig Alexander Collard

Sector: Healthcare

Employees: 126

Address: 4242 Campus Point Court, San Diego, CA 92121

Phone: 858 251 4400

Leadership

  • Adam Morgan, Chairman
  • Sharmila Dissanaike, M.D., FACS, FCCM, Director
  • Craig Johnson, Lead Independent Director
  • Susan Rodriguez, Director
  • Christian Waage, Director
  • Craig Collard, Director
  • Brett Fleshman, Chief Business Officer

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Low

LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004

Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.

Tags: APOE4, Batten disease, acquired diseases, cardiomyopathy, gene therapy, genetic medicine, hereditary diseases

Symbol: LXEO

Recent Price: $6.54

Industry: Biotechnology

CEO: Mr. R. Nolan Townsend

Sector: Healthcare

Employees: 69

Address: 345 Park Avenue South, New York, null 10010

Phone: 212-547-9879

Last updated: 2024-12-31

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. logo
Market Cap: High
Employees: Lowest

Diazoxide Choline Controlled-Release

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, including their lead candidate for Prader-Willi Syndrome.

Tags: Prader-Willi Syndrome, biopharmaceutical, clinical-stage, rare diseases, therapeutics

Symbol: SLNO

Recent Price: $45.30

Industry: Biotechnology

CEO: Dr. Anish Bhatnagar M.D.

Sector: Healthcare

Employees: 33

Address: 203 Redwood Shores Parkway, Redwood City, CA 94065

Phone: 650 213 8444

Last updated: 2024-12-31

Scilex Holding Company

Scilex Holding Company logo
Market Cap: Low
Employees: Low

ZTlido 1.8%

Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing non-opioid management products for the treatment of acute and chronic pain, including its commercial product ZTlido 1.8% and several products in clinical trial stages.

Tags: biopharmaceutical, clinical trials, neuropathic pain, non-opioid pain management

Symbol: SCLX

Recent Price: $0.42

Industry: Drug Manufacturers - General

CEO: Mr. Jaisim Shah

Sector: Healthcare

Employees: 113

Address: 960 San Antonio Road, Palo Alto, CA 94303

Phone: 650-516-4310

Last updated: 2024-12-31

Exelixis, Inc.

Exelixis, Inc. logo
Market Cap: Highest
Employees: Medium

CABOMETYX, COMETRIQ, COTELLIC, MINNEBRO

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines to treat cancers, primarily in the United States. Its products include CABOMETYX, COMETRIQ, COTELLIC, and MINNEBRO.

Tags: biotechnology, cancer treatment, oncology, pharmaceuticals

Symbol: EXEL

Recent Price: $33.70

Industry: Biotechnology

CEO: Dr. Michael M. Morrissey Ph.D.

Sector: Healthcare

Employees: 1310

Address: 1851 Harbor Bay Parkway, Alameda, CA 94502

Phone: 650 837 7000

Last updated: 2024-12-31

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. logo
Market Cap: Highest
Employees: Medium

DEFINITY, Techne Lite, Xenon-133, Neurolite, Cardiolite, Thallium-201, Gallium-67, AZEDRA, Automated Bone Scan Index, Cobalt (Co 57), RELISTOR

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

Tags: cardiovascular, diagnostic products, healthcare, oncology, radiotherapy, therapeutic products

Symbol: LNTH

Recent Price: $89.13

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Brian A. Markison

Sector: Healthcare

Employees: 834

Address: 331 Treble Cove Road, North Billerica, MA 01862

Phone: 978 671 8001

Leadership

  • Brian Markison, Chief Executive Officer
  • Paul Blanchfield, President
  • Jeff Humphrey, MD, Chief Medical Officer
  • Robert J. Marshall Jr., Chief Financial Officer
  • Amanda Morgan, Chief Commercial Officer
  • Daniel Niedzwiecki, Chief Administrative Officer, General Counsel and Corporate Secretary
  • Jean-Claude Provost, MD, Chief Science Officer
  • Jamie Spaeth, Chief People Officer
  • Cheryl Ball, Senior Vice President, Strategy and Enterprise Planning
  • Dorothy Barr, Senior Vice President, Manufacturing and Technical Operations
  • Kim Brown, Chief Accounting Officer
  • Lee Anne Howe, Chief Information Officer
  • Linda Lennox, Chief of Staff & Vice President, Corporate Communications
  • Joann Nestor, Senior Vice President, Legal Affairs
  • Andrea Sabens, Vice President, Business Optimization
  • Carol Walker, Senior Vice President, Quality
  • Mary Anne Heino, Chairperson of the Board
  • Minnie Baylor-Henry, Director
  • Gérard Ber, PhD, Director
  • Julie Eastland, Director
  • Samuel Leno, Director
  • Heinz Mäusli, Director
  • Julie McHugh, Director
  • Gary J. Pruden, Director
  • James H. Thrall, MD, Director

Last updated: 2024-12-31

Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010

Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.

Tags: ALS, Parkinson's disease, Sanfilippo syndrome, biopharmaceutical, central nervous system, major depressive disorder, respiratory disorders, therapeutics

Symbol: SEEL

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Raj Mehra J.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 300 Park Avenue, New York, NY 10022

Phone: 646 293 2100

Last updated: 2024-12-31